Key Points
-
Dendritic cells (DCs) are a specialized family of antigen-presenting cells (APCs) that effectively link innate recognition of invading pathogens to the generation of the appropriate type of adaptive immune response.
-
Among the multiple blood-borne viruses, hepatitis B virus (HBV), hepatitis C virus (HCV), HIV-1 and HIV-2 have created a global health problem of substantial proportions. Not only do they establish asymptomatic, persistent infections with potential oncogenic sequelae, but they are also important causes of morbidity and mortality.
-
Ideally positioned throughout the body's ports of entry (in the skin, at the mucosal surface and in the blood), DCs are among the primary interaction partners and form a first line of defence against these viruses.
-
Although evidence exists that DCs can be infected by HIV and probably also by HCV, DCs seem not to be targeted by these viruses for the production of viral progeny. Instead, DCs are used as a vehicle to gain access to the pool of primary target cells, such as the CD4+ T cells in the secondary lymphoid tissue, which are the primary target for HIV.
-
Accumulating evidence indicates that common viral evasion strategies have been evolved by these viruses to disturb the generation of strong antiviral innate and adaptive immune responses, such as interference with the potent antiviral interferon-α pathway in plasmacytoid DCs or alteration of the cytokine network in myeloid DCs. In addition, these viruses seem to force DCs to produce immunoregulatory enzymes that can actively suppress T cell activation.
-
A special situation occurs in the liver (which is the primary target organ for the hepatotropic viruses HBV and HCV). The tolerogenic environment and the unique composition of APCs in the liver prevent the induction of efficient virus-specific T cell priming. This situation might be exploited by these viruses to evade immunity and facilitate persistent infection.
-
As DCs are uniquely positioned for early viral encounters, they can be exploited in prophylactic and therapeutic vaccine approaches. Identification of the intracellular compartments in which these persistent viruses are processed for antigen presentation is an unexplored facet that may be exploited pharmaceutically to stimulate strong and durable cellular responses that can finally control viral replication.
Abstract
Persistent infections with HIV, hepatitis B virus and hepatitis C virus are major causes of morbidity and mortality worldwide. As sentinels of the immune system, dendritic cells (DCs) are crucial for the generation of protective antiviral immunity. Recent advances in our understanding of the role of DCs during infection with these viruses provide insights into the mechanisms used by these viruses to exploit DC function and evade innate and adaptive immunity. In this Review we highlight the current knowledge about the interaction between DCs and these viruses and the underlying mechanisms that might influence the outcome of viral infections.
Similar content being viewed by others
Main
The immune response to viral infection is a complex interplay between the virus and the innate and adaptive immune responses and is aimed at eradicating the pathogen with minimal damage to the host. Dendritic cells (DCs) are a specialized family of antigen-presenting cells (APCs) that effectively link the innate recognition of viruses to the generation of the appropriate type of adaptive immune response1. DCs are continuously produced from haematopoietic stem cells in the bone marrow and are positioned at the different portals of the human body, such as the skin, mucosal surfaces and the blood, so that they encounter invading pathogens early in the course of an infection2.
DCs are a heterogeneous family. This heterogeneity arises at several levels, including phenotype, function and anatomical location2 (Table 1). Langerhans cells form a long-lived population of stellate DCs in the epidermis; interstitial DCs comprise the DCs found in all peripheral tissues, excluding Langerhans cells. The haematopoietic stem cells also give rise to two other DC subsets in the blood: myeloid DCs (mDCs) and plasmacytoid DCs (pDCs). DCs are equipped with a set of varied pattern recognition receptors (PRRs), such as Toll-like receptors (TLRs), through which they sense and process viral information and become activated (Table 1). Following activation, DCs migrate to the regional lymph nodes, where they become mature interdigitating DCs in the T cell-dependent areas. As a result of viral-antigen uptake and presentation on the surface, in complex with major histocompatibility complex (MHC) class I and II molecules, DCs trigger an immune response in any T cell that possesses a cognate receptor specific for the viral-peptide–MHC molecule complexes being presented on the DC surface1.
The different DC subsets seem to have evolved over time to acquire both distinct and overlapping functions in order to better defend the host. Both mDCs and pDCs function in innate and adaptive immunity and provide a critical link between the two arms of immunity that respond to viral infection3. Following activation, mDCs produce interleukin-12 (IL-12) and IL-15, which in turn stimulate interferon-γ (IFNγ) secretion by natural killer (NK) cells and promote the differentiation of CD4+ T helper (TH) cells into TH1 cells and of CD8+ T cells into cytotoxic T lymphocytes; these cells contribute to viral clearance by killing infected cells either directly, through the release of cytolytic mediators such as granzyme, or indirectly, by secreting TH1-type cytokines that inhibit viral replication (Fig. 1). In contrast to mDCs, which may have evolved mainly to prime and activate antiviral T cells, pDCs are the key effector cells in the early antiviral innate immune response, as they produce large amounts of type I interferon on viral infection. Type I interferons (such as IFNα and IFNβ) released by pDCs not only have potent antiviral activity but also support subsequent steps of antiviral immunity, including the activation of NK cell-mediated cytotoxicity and CD4+ T cell and CD8+ T cell differentiation and survival4. In addition, pDCs also have an overlapping role as APCs5.
The importance of DCs in the clearance of viral infection has been shown for several viruses, such as the common respiratory viral pathogens human respiratory syncytial virus (HRSV) and influenza virus6,7. DCs also play an important part in the control of blood-borne viruses, the most common and deadly being hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency viruses (HIV-1 and HIV-2). Patients who spontaneously clear HBV and HCV infections or control HIV infection exhibit a strong multi-epitope-specific CD4+ T cell and CD8+ T cell response that probably reflects efficient priming and activation of antiviral T cells by DCs8,9,10,11. However, viral clearance after HBV, HCV or HIV infection is not always possible, and together these viruses have created a global health problem of substantial proportions. Not only do they establish asymptomatic persistent infections with potential oncogenic sequelae, but they also cause substantial morbidity and mortality (Table 2). HIV infection causes AIDS, which is characterized by profound immunosuppression and a diverse range of associated opportunistic infections12. Worldwide, HBV and HCV have infected more than 370 and 130 million people, respectively13, and are the two major causes of chronic liver disease and its associated complications (including liver cirrhosis, liver failure and hepatocellular carcinoma)14. A common denominator in all these persistent infections is the weak and narrowly focused antiviral T cell response8,9,10,11. Owing to their central role in the initiation of the antiviral immune response, DCs are ideal targets for viruses to exercise their immune evasion strategies; in fact, viruses that cause persistent infection seem to have perfected the art of evading the pathogen recognition and elimination properties of DCs (Box 1). Gaining a clearer understanding of these mechanisms in virus-infected DCs might enable us to better comprehend virus–host interactions and, in turn, might provide new perspectives for the therapy of persistent infections as well as for the design of vaccines.
This Review highlights the latest advances in our understanding of the interplay between DCs and these viruses that cause persistent viral infections. We focus on the interaction of HBV, HCV and HIV with different subtypes of DCs, outlining diverse outcomes of the virus–DC interaction and its relevance to viral pathogenesis as well as the mechanisms that these viruses have developed to interfere with the normal immune response of the host.
Do persistent viruses infect dendritic cells?
The presence of DCs in the skin, in the blood and, particularly, at the mucosal surfaces and their ability to take up antigen at these sites predisposes DCs to be primary target cells for viruses. It is therefore possible that viruses establish persistence by directly infecting DCs. It is not unreasonable to assume that replication of the viral genome, along with the expression of viral antigens, would interfere with signalling pathways in DCs or directly impair DC function, rendering infected DCs less able to stimulate T cell responses. For example, ICP47 of herpes simplex virus 1 (HSV1) and US6 of human herpesvirus 5 (HHV5) are known to inhibit loading of antigenic peptides onto MHC class I molecules, thereby interfering with the ability of infected DCs to prime naive T cells efficiently15.
HIV. Langerhans cells, the APCs of the epidermis, were the first DCs reported to be susceptible to HIV-1 infection. Since then, mDCs and pDCs isolated from the blood of patients infected with HIV-1 have been shown to be infected by the virus (reviewed in Ref 16). However, HIV-1 replication in DCs is usually less productive, and the frequency of HIV-1-infected DCs in vivo is often 10–100 times lower than that of HIV-1-infected CD4+ T cells17. In vitro studies indicate that, on average, only 1–3% of mDCs and pDCs from healthy blood donors can be productively infected by primary HIV-1 and by laboratory-adapted HIV-1, as detected by intracellular staining of capsid protein p24 from HIV-118. Immature DCs have been reported to be more susceptible to productive infection than mature DCs19, which can be partly explained by the enhanced capacity of immature DCs to acquire viral antigen. During maturation of DCs, their ability to capture antigens through macropinocytosis and receptor-mediated endocytosis rapidly declines and, instead, the DCs assemble complexes of antigen with either MHC class I or MHC class II molecules1. Furthermore, HIV replication in pDCs was observed to increase substantially following CD40 ligation20 (a signal that is delivered physiologically by CD4+ T cells). Thus, HIV replication in pDCs may be triggered through the interaction with activated CD4+ T cells in the extrafollicular T cell zones of the lymphoid tissue, suggesting that pDCs serve as viral reservoirs for CD4+ T cells.
HCV. Genomic RNA from HCV has been detected in pDCs and mDCs that were isolated from the blood of patients infected with the virus21,22, and so it was initially thought that DCs were susceptible to HCV infection. However, using a strand-specific semi-quantitative reverse transcription PCR (RT-PCR), the replicative intermediate was observed in DCs isolated from only 3 out of 24 patients infected with HCV21, indicating that HCV replication occurs at a lower frequency in DCs than in hepatocytes, which are the main site of HCV replication. To study HCV infection of DCs in vitro, monocyte-derived DCs from healthy individuals were incubated with serum from HCV-infected patients. The replicative intermediate was subsequently detected in these DCs, indicating that they may support at least the first steps of the viral life cycle23. However, following incubation of monocyte-derived DCs and subsets of blood DCs with infectious recombinant HCV (Box 2), neither viral replication nor viral protein synthesis could be detected24,25,26,27,28, suggesting that HCV may infect DCs but does not result in a productive infection.
HBV. Although the detection of HBV DNA in subsets of isolated blood DCs from patients infected with HBV has been proposed to indicate HBV infection of DCs29, additional studies have not revealed the presence of RNA replicative intermediates in either blood DC subsets from patients infected with HBV or in DCs infected in vitro with wild-type or recombinant HBV30,31. Thus, it is likely that DCs do not support the replication and production of HBV viral particles and that the detection of HBV DNA merely reflects the attachment of the virus to the cell surface or the natural antigen uptake function of DCs.
In summary, DCs can support the production of HIV particles, although at a much lower level than is supported by CD4+ T cells (which are the primary targets for HIV), but cannot support the production of HCV and HBV particles, even though HCV may be able to initiate replication. There are three possible explanations for this.
First, viral receptors or co-receptors may be absent or present only at a low frequency on DCs. DCs express low levels of the principal HIV receptor, CD4, and the co-receptors CC-chemokine receptor 5 (CCR5) and CXC-chemokine receptor 4 (CXCR4)32 and very low levels of the HCV co-receptor claudin 1 (Ref. 28). Unlike HIV and HCV, functional receptors that mediate the entry of HBV have not yet been identified.
Second, the virus may be degraded in intracellular compartments in DCs before it completes its replicative cycle. Antigens can be targeted to different processing pathways after internalization through receptor-mediated endocytosis, and the endocytosed antigen undergoes extensive degradation before its presentation on the cell surface in association with MHC class I and MHC class II molecules33. DC-specific ICAM3-grabbing non-integrin (DC-SIGN; also known as CD209), a C-type lectin receptor34, has been shown to promote HIV antigen presentation by MHC class I and MHC class II molecules35,36. Scavenger receptor class B member 1 (SRB1) is known to mediate the uptake and presentation of HCV particles by DCs37.
Third, host factors may block viral replication, or host factors required for replication may be missing in DCs. HBV replication was shown to be dependent on the presence of liver-specific transcription factors belonging to a family of nuclear hormone receptors38. Members of a family of cellular restriction factors, the APOBEC (apolipoprotein B mRNA-editing enzyme, catalytic polypeptide) cytidine deaminase family, block replication of HIV after viral entry39. Expression levels of APOBEC-like 3G (APOBEC3G) in mDCs correlate with HIV resistance40, suggesting that cytidine deaminases are potent innate barriers to HIV infection. The presence of host restriction factors might be a crucial factor in determining the susceptibility of DC populations to productive infection with persistent viruses.
The role of dendritic cells in viral dissemination
After uptake of viral antigen, activated DCs can traffic extensively from peripheral tissues to secondary lymphoid organs in an effort to present viral antigens to naive T cells. It is therefore not surprising that persistent viruses exploit this migratory property of DCs to disseminate to more favourable sites of replication.
HIV. It has been known for more than a decade that DCs efficiently transmit HIV to CD4+ T cells. One potential mechanism of HIV transfer from DCs to T cells involves DC-SIGN (reviewed in Ref. 16). DC-SIGN-mediated binding of HIV requires the interaction of the HIV envelope glycoprotein gp120 with the carbohydrate recognition domain of DC-SIGN. HIV is subsequently internalized into non-lysosomal compartments and transported within DCs before it is transferred to CD4+ T cells in a process termed trans-infection. The sequential endocytosis and exocytosis of intact HIV virions, without viral replication, is called the 'Trojan Horse' model. In this model, virion transmission is thought to occur through the infectious synapse41 (a structure that is formed between DCs and T cells) and is mediated by viral receptors, co-receptors and DC-SIGN or other C-type lectins. Because DCs can sequester infectious viruses for several days in their endosomal compartments, DCs can carry HIV to interacting T cells in the lymph node, which is the most important site for viral replication and spread42. Direct HIV infection of DCs can also occur, although it is less efficient than infection of CD4+ T cells. Several reports indicate that HIV dissemination may be aided by the transfer of progeny virus from infected DCs to T cells43,44 in a process known as cis-infection. It is possible that DCs form a long-lived, motile HIV reservoir that helps to disseminate infectious virus through peripheral blood and lymphoid and non-lymphoid tissues.
The differences between the DC subsets (Table 1) raise the possibility that they have distinct roles in HIV transmission. For example, HIV transmission is less efficient in pDCs than in mDCs45. In addition, although mDC subsets are known to efficiently transfer HIV to activated CD4+ T cells16, Langerhans cells seem to prevent HIV transmission by degrading captured HIV particles46, suggesting that distinct DC subsets can either mediate or prevent HIV transmission.
HCV. Compared with HIV research, studies analysing the in vivo dissemination of hepatotropic viruses by DCs are in their infancy. The HCV envelope glycoprotein E2, HCV virions from serum samples taken from patients infected with HCV, and retroviruses that were pseudotyped with HCV envelope glycoproteins (known as HCV pseudoviruses) have been shown to bind specifically to DC-SIGN47,48,49. Thus, it may be possible that blood DCs or hepatic DCs in the liver sinusoids bind circulating HCV particles through a DC-SIGN-mediated mechanism. Of note, HCV pseudovirus bound to the DC-SIGN that was expressed on monocyte-derived DCs was transmitted efficiently when co-cultured with the human hepatocellular carcinoma cell line Huh7 (a cell line that supports HCV pseudovirus entry and productive viral replication of recombinant infectious HCV)49,50. Furthermore, virus-like particles, which are representative of HCV envelope glycoproteins, are bound by DC-SIGN and are targeted to early-endosomal vesicles or non-lysosomal compartments in monocyte-derived DCs. The HCV particles resided in these compartments for over 24 hours51, suggesting that HCV can bypass the antigen processing and presentation pathways in DCs, thereby escaping degradation. It is possible that HCV retained in the non-lysosomal compartments of DCs plays a part in HCV transmission from DCs to hepatocytes. HCV captured by blood DCs or hepatic DCs in the liver sinusoids may allow transfer of the virus to the underlying hepatocytes when DCs traverse the sinusoidal lumen to the hepatic lymph. Similarly to DCs, liver sinusoidal endothelial cells (LSECs), which form the endothelial lining of the hepatic sinusoid (Fig. 2), have been shown to bind recombinant HCV E2 protein through the interaction of the DC-SIGN and DC-SIGN-related protein (DC-SIGNR; also known as CLEC4M) that are present on the surface of LSECs52. However, LSECs cannot support HCV pseudovirus entry and infection with HCV derived from cell culture, suggesting that LSECs are not permissive for HCV infection52. Nonetheless, DC-SIGN-mediated binding of HCV to LSECs might support a model whereby this binding provides a mechanism for high-affinity binding of circulating HCV in the liver sinusoid, allowing subsequent transfer of the virus to the underlying hepatocytes and therefore increasing the rate and efficiency of their infection.
HBV. Although DC-SIGN recognizes a broad range of pathogens, from bacteria to viruses, binding to DC-SIGN has not been observed so far for recombinant HBV surface antigen or for HBV particles derived from cell culture53. Interestingly, studies have shown that enzymatic modification of the N-linked oligosaccharide structures of the HBV antigen prevents recognition by DC-SIGN53, although other mechanisms might also have a role.
The impact on dendritic cell function
Effects of persistent viruses on DCs in vivo. Virus-mediated impairment of DC function (Table 3) is a strategy to attenuate the multiple downstream immune effector mechanisms that depend on optimal DC function, and it might facilitate viral persistence.
At the primary level, viruses can modulate the frequency of DC subsets by interfering with DC development, causing aberrant trafficking or inducing apoptosis. Lower numbers of blood mDCs and pDCs have been observed in patients infected with HIV54,55,56,57,58,59, HCV60,61,62,63,64,65 and HBV66 than in uninfected individuals. In HIV infection, DC depletion seems to be due to the migration of pDCs to the inflamed lymph nodes, where they have been found to be activated, apoptotic and frequently infected with virus67,68, suggesting that HIV-mediated cell death may account for the decreased number of circulating pDCs. In HCV or HBV infection, blood DC subsets are enriched in the liver64,69,70,71, suggesting that DC migration to the liver causes the observed paucity of circulating DCs. However, lower numbers of circulating DCs have also been observed in patients with liver diseases that are not related to viral infection, such as granulomatous hepatitis or primary biliary cirrhosis27,61,72, suggesting that the low DC count in virus-related liver diseases is a common, nonspecific feature of inflammatory hepatitis. Interestingly, in vitro studies revealed that HCV envelope glycoprotein E2 and sera from patients infected with HCV inhibit the migration of DCs towards CC-chemokine ligand 21 (CCL21), a CCR7-binding chemokine that is important for homing to lymph nodes64. This leads to the hypothesis that after HCV uptake DCs may experience an impaired ability to migrate to the draining lymph node, causing them to be trapped in the liver and, therefore, to be less able to prime T cell responses. However, the in vivo relevance of this hypothesis remains to be investigated.
Differentiation and activation of virus-specific TH1 cells and cytotoxic T lymphocytes from CD4+ T cells and CD8+ T cells, respectively, are regulated by DC-mediated production of IL-12. DC-mediated production of IL-10, on the other hand, is capable of inhibiting these responses3. Upregulation of IL-10 production and suppression of IL-12 and IFNα in response to various maturation stimuli have been documented in monocyte-derived DCs, mDCs and pDCs isolated from patients infected with HIV73,74,75, HCV63,65,76,77 and HBV29. Furthermore, dysregulated cytokine production by DCs might affect the early antiviral defence mediated by NK cells (Fig. 1). Several lines of evidence indicate that NK cell activity is impaired during HIV infection, in part owing to defective pDC function78,79. In particular, defective production of IFNγ by NK cells was attributable to impaired pDC function79. Whether the defective production of IFNγ that is seen in NK cells of patients with a chronic HCV infection80 relies also on impaired crosstalk between DCs and NKs remains to be investigated.
DCs isolated from patients infected with HIV73,74,75, HCV63,81,82,83 and HBV29 were less able to stimulate T cell activation and proliferation than cells from uninfected individuals, as seen in a mixed lymphocyte reaction. Less efficient allogeneic T cell stimulation by DCs from patients infected with HIV84 or HCV82 could be reversed by the neutralization of IL-10, suggesting that virus-induced production of IL-10 by DCs might limit T cell proliferation and activation, skewing the immune response towards tolerance. However, several investigators failed to detect impaired stimulation of allogeneic T cells by DCs isolated from patients infected with HCV60,61,62,72,85 and HBV86. Possible reasons for these contradictory results are that different experimental and technical settings were used (for example, different isolation protocols or maturation cocktails), that DCs might respond differently depending on their maturation status and uptake of viral antigen, and that the viral load in the infected patients might have varied. In addition, DC dysfunction during infection with hepatotropic viruses may be restricted to the virus-specific response, as the strong global immune dysfunction seen in HIV/AIDS is not observed with HBV and HCV infection.
To gain a different perspective on the impact of persistent viruses on DCs, DC number and function have been studied before and during antiviral therapy. Highly active antiretroviral therapy (HAART) for HIV infection resulted in an increase in pDC number and restoration of IFNα production to normal levels78,87, indicating that antiretroviral therapy that reduces viral load can reconstitute the function of DCs. Likewise, following therapy with pegylated IFNα and ribavirin for HCV infection, the frequency of pDCs in individuals with viral clearance increased substantially and reached levels observed in uninfected controls88. Therapy for HBV infection with the nucleotide analogue adefovir dipivoxil increased the frequency of mDCs and their ability to produce IL-12 as well as the T cell stimulatory capacity, whereas the production of IL-10 decreased30. This functional recovery of mDCs coincided with a notable reduction in viral load, underscoring the importance of a reduction in viral load for antiviral regimens; this reduction serves as the first step in a multistep process that culminates in the restoration of impaired immune responses during recovery from persistent viral infections.
In vitro studies to investigate the molecular mechanisms of the virus–DC interaction. To clarify the impact of persistent viruses on DC function and to identify the molecular mechanisms involved in this interaction, DC subsets isolated from uninfected individuals have been exposed directly to recombinant infectious virus or viral proteins. In contrast to HIV89 and other viruses, such as influenza virus and HSV1 (Refs 25, 90, 91, 92), recombinant and serum-derived HCV and HBV have been shown to be poor inducers of IFNα production in pDCs24,25,65,90, suggesting that these viruses may use this mechanism to downregulate downstream effector functions that are dependent on pDC-mediated IFNα production. In pDCs, TLR7 and TLR9 detect viral RNA and DNA, respectively, in endosomal compartments, leading to the activation of nuclear factor-κB (NF-κB) and IFN regulatory factors (IRFs)4. IFNα production induced by CpG oligodeoxynucleotides, the TLR9 agonist, but not by resiquimod, the TLR7 agonist, was inhibited by HCV24,25,90 and HBV93. Similarly, HIV inhibited TLR9-mediated IFNα production59,94, indicating that impairment of IFNα production in pDCs is a strategy that is used universally by persistent viruses. What are the underlying mechanisms responsible for this viral interference in the IFNα pathway of pDCs? A possible mechanism could be related to viral cross-linking of cell surface receptors that downregulate IFNα production, such as the C-type lectins blood DC antigen 2 (BDCA2; also known as CLEC4C) and dendritic cell immunoreceptor (DCIR; also known as CLEC4A). It has been shown that BDCA2 and DCIR ligation and cross-linking results in the inhibition of CpG-mediated induction of IFNα by pDCs95,96. The viral envelope proteins HBV surface antigen (HBsAg) and HIV gp120 can directly impair TLR9-mediated IFNα production by pDCs through binding BDCA2 (Refs 93, 94). Although TLR9-mediated IFNα production was blocked by HCV core particles24 and recombinant non-infectious HCV particles composed of HCV core and the envelope glycoproteins E1 and E2 (Refs 24, 25, 90), it is not known whether the interaction also occurs through BDCA2.
Recent studies indicate that persistent viruses may target immunosuppressive enzymes in DCs to actively suppress antiviral T cell immune responses. The tryptophan-catabolizing indoleamine 2,3-dioxygenase (IDO) activity seems to be a central feature of the suppressive function of DCs. DC-mediated IDO activity has been associated with inhibition of T cell proliferation and function97. In vitro activated human T cells underwent cell cycle arrest when deprived of tryptophan98, and T cells became susceptible to apoptosis in vitro and in vivo in response to the toxic metabolites generated during tryptophan degradation99. Direct exposure of DCs to HIV induces IDO activity, leading to the inhibition of CD4+ T cell proliferation in vitro100. Moreover, HIV-stimulated IDO activity in pDCs induces the differentiation of naive T cells into CD4+CD25+FOXP3+ regulatory T cells with suppressive function101, suggesting that HIV-induced IDO activity may contribute to viral persistence by suppressing virus-specific T cell responses. In simian immunodeficiency virus (SIV)-infected macaques, peak IDO activity coincided with an increase in plasma viraemia and the transient expansion of the regulatory CD8+CD25+FOXP3+ T cell subset that may participate in dampening the SIV-specific CD4+ T cell response102. As enhanced IDO activity has been observed in patients infected with HIV, HCV and HBV103,104,105, the role of DC-mediated IDO activity in viral persistence merits further investigation.
In summary, several lines of evidence indicate that viruses efficiently target DC function to attenuate the antiviral host immune response and establish persistence. But is there also a role for DCs in disease progression? Chronic HBV and HCV infections are major risk factors for the development of hepatocellular carcinoma14. There is increasing evidence that a long-standing inflammatory injury is an important procarcinogenic factor in many different cancer types, including hepatocellular carcinoma106. The host DC immune response to hepatitis viruses is fairly weak and often fails to control or completely clear infection, resulting in chronic stimulation of the antigen-specific immune response in persistently infected patients. Chronic antigen stimulation at the infection sites and continuous infiltration of DCs into liver tissue may perpetuate a long-lasting chronic inflammatory process owing to the continued expression of pro-inflammatory cytokines, the accompanying activation of liver NK cells and the recruitment of T cells. These events may affect many cellular pathways and ultimately result in fibrosis, cirrhosis or hepatocellular carcinoma. In HIV infection, it is widely accepted that chronic immune activation has a central role in driving the progression to AIDS107. Recent reports indicate that chronic pDC stimulation and IFNα production are associated with a higher risk of progression to AIDS108,109, underscoring the role of pDCs in the disease. A detailed comparison of the complex processes that govern homeostasis and immune activation mechanisms in health and persistent viral infection may help define the contribution of DCs to disease pathogenesis.
The role of hepatic antigen-presenting cells
The liver has several cell populations that can act as APCs. As well as liver DCs, LSECs, stellate cells and Kupffer cells110 (Fig. 2) can present antigens and influence the generation and maintenance of the antiviral immune responses. However, the liver-specific immune system is maintained at a baseline state of tolerance, as evidenced by the spontaneous acceptance of liver allografts111. Several types of liver APCs exist in a state of active tolerance and contribute to the tolerogenic liver environment by the continuous secretion of immunosuppressive cytokines, for example, IL-10 and transforming growth factor β1 (TGFβ1)112. This raises the question of whether the tolerogenic properties of liver APCs contribute to the persistence of hepatotropic viruses and whether the liver is a unique environment for immune evasion.
Owing to the difficulty in gaining access to liver biopsies and the challenge of isolating adequate numbers of APCs from tissue (and of obtaining high-purity samples), limited information is available regarding the role of hepatic APCs in viral infection. In isolated Kupffer cells that were incubated with sera containing HCV RNA (from patients infected with HCV)113, genomic RNA from HCV disappeared within a few days of infection and the replicative intermediate could not be detected, suggesting that Kupffer cells do not support HCV replication. Similarly, isolated LSECs were unable to support infection by HCV and HBV derived from cell culture, suggesting that LSECs are not permissive for hepatotropic viruses52,114.
An analysis of liver biopsy samples obtained from patients with chronic HCV infection demonstrated that most Kupffer cells express high levels of co-stimulatory molecules, MHC class I molecules and MHC class II molecules and form clusters with CD4+ T cells, thereby acquiring the phenotype of an effective APC115. As Kupffer cells are able to move across the sinusoidal wall into the liver parenchyma, their activation might reflect phagocytosis of HCV-infected apoptotic hepatocytes. Although there is little doubt that liver DCs can take up viral particles, available evidence indicates that this may not translate to efficient T cell priming and activation. In vivo studies have revealed that hepatic DCs and LSECs do present exogenous antigen to naive T cells, but the resulting activated T cells either fail to differentiate into effector T cells or acquire an immunosuppressive phenotype (for reviews, see Refs 112, 116). It is possible that the uptake of viral particles by liver APCs primes CD4+CD25+FOXP3+ regulatory T cells and impairs CD8+ T cells such that they fail to eradicate the virus from the liver. As antigen-specific CD8+ T cells in the liver of patients with chronic HCV infection frequently become dysfunctional and unable to secrete IFNγ or IL-2 (Ref. 117), the role of hepatic DCs in HCV-specific T cell priming merits further investigation.
Current research has not focused on the ability of the hepatocyte to act as an APC in HCV infection. In general, hepatocytes are not easily accessible to naive T cells, because LSECs form an effective barrier between hepatocytes and the sinusoidal lumen118. However, electron microscopy analysis has shown that hepatocytes have microvilli that project into the sinusoidal lumen through the fenestrations in the endothelium, allowing contact between hepatocytes and circulating T cells in the lumen119. Hepatocytes do not normally express MHC class II molecules; however, aberrant expression of MHC class II molecules has been demonstrated in clinical hepatitis120,121. It is therefore possible that hepatocytes expressing MHC class II molecules stimulate CD4+ T cells or shape the antiviral immune response of pre-activated CD4+ T cells. Additional studies in transgenic mice showed that CD8+ T cells might be directly activated by hepatocytes. However, this activation seems to favour an impaired cytotoxic T lymphocyte response and reduced host survival, possibly caused by a lack of co-stimulatory molecules122,123. Thus, presentation of viral antigens by hepatocytes may influence the antiviral immune response and seems to promote CD8+ T cell dysfunction.
Conclusions and perspectives
Accumulating evidence indicates that HIV, HCV and HBV target DC functions to disturb the generation of strong antiviral innate and adaptive immune responses, facilitating viral persistence. All three viruses seem to use similar strategies to attenuate the potent antiviral IFNα response in pDCs. In addition, these viruses seem to affect the ability of mDCs to produce key cytokines that are essential for the development and activation of an effective T cell response. Not only do these viruses override the natural antiviral activity of the DCs, but they also use the DCs as vehicles for widespread dissemination within the host.
In the future, key issues for improving our understanding of the interplay between persistent viruses and DCs are: the characterization of the intracellular compartments and molecular mechanisms that are required for virus acquisition, processing and presentation by DCs; the identification of mechanisms regulating the balance between intra-hepatic tolerance and immunity; and the role of DCs in aiding viral transmission during infection with HBV and HCV. Not only will knowledge of these mechanisms help us to understand viral pathogenesis, but it can also be used to design strategies that manipulate the immune system towards generating a protective immune response that controls viral replication without the associated immunopathology.
References
Banchereau, J. & Steinman, R. M. Dendritic cells and the control of immunity. Nature 392, 245–252 (1998). This article elegantly describes the basics of DC function.
Wu, L. & Liu, Y. J. Development of dendritic-cell lineages. Immunity 26, 741–750 (2007).
Steinman, R. M. & Haemmi, H. Dendritic cells: translating innate to adaptive immunity. Curr. Top. Microbiol. Immunol. 311, 17–58 (2006). An overview of the development and role of the different DC subsets.
Liu, Y. J. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu. Rev. Immunol. 23, 275–306 (2005).
Colonna, M., Trinchieri, G. & Liu, Y. J. Plasmacytoid dendritic cells in immunity. Nature Immunol. 5, 1219–1226 (2004).
Smit, J. J. et al. The balance between plasmacytoid DC versus conventional DC determines pulmonary immunity to virus infections. PLoS ONE 3, e1720 (2008).
GeurtsvanKessel, C. H. et al. Clearance of influenza virus from the lung depends on migratory langerin+CD11b− but not plasmacytoid dendritic cells. J. Exp. Med. 205, 1621–1634 (2008).
Rehermann, B. & Nascimbeni, M. Immunology of hepatitis B virus and hepatitis C virus infection. Nature Rev. Immunol. 5, 215–229 (2005).
Guidotti, L. G. & Chisari, F. V. Immunobiology and pathogenesis of viral hepatitis. Annu. Rev. Pathol. 1, 23–61 (2006).
Gandhi, R. T. & Walker, B. D. Immunologic control of HIV-1. Annu. Rev. Med. 53, 149–172 (2002).
McMichael, A. J. & Rowland-Jones, S. L. Cellular immune responses to HIV. Nature 410, 980–987 (2001). This and reference 8 offer a comparison of the clinical, virological and immunological features of HBV and HCV infections, providing an excellent overview of the antiviral adaptive immune response in persistent viral infections.
Simon, V., Ho, D. D. & Abdool Karim, Q. HIV/AIDS epidemiology, pathogenesis, prevention, and treatment. Lancet 368, 489–504 (2006).
Alter, M. J. Epidemiology of viral hepatitis and HIV co-infection. J. Hepatol. 44, S6–S9 (2006).
Williams, R. Global challenges in liver disease. Hepatology 44, 521–526 (2006).
Bauer, D. & Tampe, R. Herpes viral proteins blocking the transporter associated with antigen processing TAP – from genes to function and structure. Curr. Top. Microbiol. Immunol. 269, 87–99 (2002).
Wu, L. & KewalRamani, V. N. Dendritic-cell interactions with HIV: infection and viral dissemination. Nature Rev. Immunol. 6, 859–868 (2006).
McIlroy, D. et al. Infection frequency of dendritic cells and CD4+ T lymphocytes in spleens of human immunodeficiency virus-positive patients. J. Virol. 69, 4737–4745 (1995).
Smed-Sörensen, A. et al. Differential susceptibility to human immunodeficiency virus type 1 infection of myeloid and plasmacytoid dendritic cells. J. Virol. 79, 8861–8869 (2005).
Canque, B. et al. The susceptibility to X4 and R5 human immunodeficiency virus-1 strains of dendritic cells derived in vitro from CD34+ haematopoietic progenitor cells is primarily determined by their maturation stage. Blood 93, 3866–3875 (1999).
Fong, L., Mengozzi, M., Abbey, N. W., Herndier, B. G. & Engleman, E. G. Productive infection of plasmacytoid dendritic cells with human immunodeficiency virus type 1 is triggered by CD40 ligation. J. Virol. 76, 11033–11041 (2002).
Goutagny, N. et al. Evidence of viral replication in circulating dendritic cells during hepatitis C virus infection. J. Infect. Dis. 187, 1951–1958 (2003).
Rodrigue-Gervais, I. G. et al. Poly(I:C) and lipopolysaccharide innate sensing functions of circulating human myeloid dendritic cells are affected in vivo in hepatitis C virus-infected patients. J. Virol. 81, 5537–5546 (2007).
Navas, M. C. et al. Dendritic cell susceptibility to hepatitis C virus genotype 1 infection. J. Med. Virol. 67, 152–161 (2002).
Liang, H. et al. Differential effects of hepatitis C virus JFH1 on human myeloid and plasmacytoid dendritic cells. J. Virol. 83, 5693–5707 (2009).
Shiina, M. & Rehermann, B. Cell culture-produced hepatitis C virus impairs plasmacytoid dendritic cell function. Hepatology 47, 385–395 (2008).
Ebihara, T., Shingai, M., Matsumoto, M., Wakita, T. & Seya, T. Hepatitis C virus-infected hepatocytes extrinsically modulate dendritic cell maturation to activate T cells and natural killer cells. Hepatology 48, 48–58 (2008).
Decalf, J. et al. Plasmacytoid dendritic cells initiate a complex chemokine and cytokine network and are a viable drug target in chronic HCV patients. J. Exp. Med. 204, 2423–2437 (2007).
Marukian, S. et al. Cell culture-produced hepatitis C virus does not infect peripheral blood mononuclear cells. Hepatology 48, 1843–1850 (2008).
van der Molen, R. G. et al. Functional impairment of myeloid and plasmacytoid dendritic cells of patients with chronic hepatitis B. Hepatology 40, 738–746 (2004).
van der Molen, R. G., Sprengers, D., Biesta, P. J., Kusters, J. G. & Janssen, H. L. Favorable effect of adefovir on the number and functionality of myeloid dendritic cells of patients with chronic HBV. Hepatology 44, 907–914 (2006).
Untergasser, A. et al. Dendritic cells take up viral antigens but do not support the early steps of hepatitis B virus infection. Hepatology 43, 539–547 (2006).
Lee, B., Sharron, M., Montaner, L. J., Weissman, D. & Doms, R. W. Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages. Proc. Natl Acad. Sci. USA 96, 5215–5220 (1999).
Jensen, P. E. Recent advances in antigen processing and presentation. Nature Immunol. 8, 1041–1048 (2007).
Cambi, A., Koopman, M. & Figdor, C. G. How C-type lectins detect pathogens. Cell. Microbiol. 7, 481–488 (2005).
Moris, A. et al. DC-SIGN promotes exogenous MHC-I-restricted HIV-1 antigen presentation. Blood 103, 2648–2654 (2004).
Smith, A. L. et al. Leukocyte-specific protein 1 interacts with DC-SIGN and mediates transport of HIV to the proteasome in dendritic cells. J. Exp. Med. 204, 421–430 (2007).
Barth, H. et al. Scavenger receptor class B is required for hepatitis C virus uptake and cross-presentation by human dendritic cells. J. Virol. 82, 3466–3479 (2008).
Tang, H. & McLachlan, A. Transcriptional regulation of hepatitis B virus by nuclear hormone receptors is a critical determinant of viral tropism. Proc. Natl Acad. Sci. USA 98, 1841–1846 (2001).
Chiu, Y. L. et al. Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells. Nature 435, 108–114 (2005).
Peng, G. et al. Myeloid differentiation and susceptibility to HIV-1 are linked to APOBEC3 expression. Blood 110, 393–400 (2007).
Piguet, V. & Sattentau, Q. Dangerous liaisons at the virological synapse. J. Clin. Invest. 114, 605–610 (2004). A description of cell to cell transmission of retroviruses through the virological synapse.
Geijtenbeek, T. B. et al. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 100, 587–597 (2000).
Burleigh, L. et al. Infection of dendritic cells (DCs), not DC-SIGN-mediated internalization of human immunodeficiency virus, is required for long-term transfer of virus to T cells. J. Virol. 80, 2949–2957 (2006).
Turville, S. G. et al. Immunodeficiency virus uptake, turnover, and 2-phase transfer in human dendritic cells. Blood 103, 2170–2179 (2004).
Groot, F., van Capel, T. M., Kapsenberg, M. L., Berkhout, B. & de Jong, E. C. Opposing roles of blood myeloid and plasmacytoid dendritic cells in HIV-1 infection of T cells: transmission facilitation versus replication inhibition. Blood 108, 1957–1964 (2006).
de Witte, L. et al. Langerin is a natural barrier to HIV-1 transmission by Langerhans cells. Nature Med. 13, 367–371 (2007).
Gardner, J. P. et al. L-SIGN (CD 209L) is a liver-specific capture receptor for hepatitis C virus. Proc. Natl Acad. Sci. USA 100, 4498–4503 (2003).
Pohlmann, S. et al. Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR. J. Virol. 77, 4070–4080 (2003).
Lozach, P. Y. et al. DC-SIGN and L-SIGN are high affinity binding receptors for hepatitis C virus glycoprotein E2. J. Biol. Chem. 278, 20358–20366 (2003).
Cormier, E. G. et al. L-SIGN (CD209L) and DC-SIGN (CD209) mediate transinfection of liver cells by hepatitis C virus. Proc. Natl Acad. Sci. USA 101, 14067–14072 (2004).
Ludwig, I. S. et al. Hepatitis C virus targets DC-SIGN and L-SIGN to escape lysosomal degradation. J. Virol. 78, 8322–8332 (2004).
Lai, W. K. et al. Expression of DC-SIGN and DC-SIGNR on human sinusoidal endothelium: a role for capturing hepatitis C virus particles. Am. J. Pathol. 169, 200–208 (2006).
Op den Brouw, M. L. et al. Branched oligosaccharide structures on HBV prevent interaction with both DC-SIGN and L-SIGN. J. Viral Hepat. 15, 675–683 (2008).
Donaghy, H. et al. Loss of blood CD11c+ myeloid and CD11c− plasmacytoid dendritic cells in patients with HIV-1 infection correlates with HIV-1 RNA virus load. Blood 98, 2574–2576 (2001).
Pacanowski, J. et al. Reduced blood CD123+ (lymphoid) and CD11c+ (myeloid) dendritic cell numbers in primary HIV-1 infection. Blood 98, 3016–3021 (2001).
Grassi, F. et al. Depletion in blood CD11c-positive dendritic cells from HIV-infected patients. AIDS 13, 759–766 (1999).
Chehimi, J. et al. Persistent decreases in blood plasmacytoid dendritic cell number and function despite effective highly active antiretroviral therapy and increased blood myeloid dendritic cells in HIV-infected individuals. J. Immunol. 168, 4796–4801 (2002).
Soumelis, V. et al. Depletion of circulating natural type 1 interferon-producing cells in HIV-infected AIDS patients. Blood 98, 906–912 (2001).
Cavaleiro, R. et al. Major depletion of plasmacytoid dendritic cells in HIV-2 infection, an attenuated form of HIV disease. PLoS Pathog. 5, e1000667 (2009).
Ulsenheimer, A. et al. Plasmacytoid dendritic cells in acute and chronic hepatitis C virus infection. Hepatology 41, 643–651 (2005).
Wertheimer, A. M., Bakke, A. & Rosen, H. R. Direct enumeration and functional assessment of circulating dendritic cells in patients with liver disease. Hepatology 40, 335–345 (2004).
Longman, R. S., Talal, A. H., Jacobson, I. M., Rice, C. M. & Albert, M. L. Normal functional capacity in circulating myeloid and plasmacytoid dendritic cells in patients with chronic hepatitis C. J. Infect. Dis. 192, 497–503 (2005).
Kanto, T. et al. Reduced numbers and impaired ability of myeloid and plasmacytoid dendritic cells to polarize T helper cells in chronic hepatitis C virus infection. J. Infect. Dis. 190, 1919–1926 (2004).
Nattermann, J. et al. Hepatitis C virus E2 and CD81 interaction may be associated with altered trafficking of dendritic cells in chronic hepatitis C. Hepatology 44, 945–954 (2006).
Dolganiuc, A. et al. Hepatitis C virus (HCV) core protein-induced, monocyte-mediated mechanisms of reduced IFN-α and plasmacytoid dendritic cell loss in chronic HCV infection. J. Immunol. 177, 6758–6768 (2006).
Xie, Q. et al. Patients with chronic hepatitis B infection display deficiency of plasmacytoid dendritic cells with reduced expression of TLR9. Microbes Infect. 11, 515–523 (2009).
Brown, K. N., Wijewardana, V., Liu, X. & Barratt-Boyes, S. M. Rapid influx and death of plasmacytoid dendritic cells in lymph nodes mediate depletion in acute simian immunodeficiency virus infection. PLoS Pathog. 5, e1000413 (2009).
Meyers, J. H. et al. Impact of HIV on cell survival and antiviral activity of plasmacytoid dendritic cells. PLoS ONE 2, e458 (2007).
Kunitani, H., Shimizu, Y., Murata, H., Higuchi, K. & Watanabe, A. Phenotypic analysis of circulating and intrahepatic dendritic cell subsets in patients with chronic liver diseases. J. Hepatol. 36, 734–741 (2002).
Lai, W. K. et al. Hepatitis C is associated with perturbation of intrahepatic myeloid and plasmacytoid dendritic cell function. J. Hepatol. 47, 338–347 (2007).
Zhang, Z. et al. Severe dendritic cell perturbation is actively involved in the pathogenesis of acute-on-chronic hepatitis B liver failure. J. Hepatol. 49, 396–406 (2008).
Longman, R. S., Talal, A. H., Jacobson, I. M., Albert, M. L. & Rice, C. M. Presence of functional dendritic cells in patients chronically infected with hepatitis C virus. Blood 103, 1026–1029 (2004).
Donaghy, H., Gazzard, B., Gotch, F. & Patterson, S. Dysfunction and infection of freshly isolated blood myeloid and plasmacytoid dendritic cells in patients infected with HIV-1. Blood 101, 4505–4511 (2003).
Chougnet, C. A., Margolis, D., Landay, A. L., Kessler, H. A. & Shearer, G. M. Contribution of prostaglandin E2 to the interleukin-12 defect in HIV-infected patients. AIDS 10, 1043–1045 (1996).
Chehimi, J. et al. Impaired interleukin 12 production in human immunodeficiency virus-infected patients. J. Exp. Med. 179, 1361–1366 (1994).
Kanto, T. et al. Impaired allostimulatory capacity of peripheral blood dendritic cells recovered from hepatitis C virus-infected individuals. J. Immunol. 162, 5584–5591 (1999).
Dolganiuc, A. et al. Hepatitis C virus core and nonstructural protein 3 proteins induce pro- and anti-inflammatory cytokines and inhibit dendritic cell differentiation. J. Immunol. 170, 5615–5624 (2003).
Chehimi, J. et al. Baseline viral load and immune activation determine the extent of reconstitution of innate immune effectors in HIV-1-infected subjects undergoing antiretroviral treatment. J. Immunol. 179, 2642–2650 (2007).
Conry, S. J. et al. Impaired plasmacytoid dendritic cell (PDC)-NK cell activity in viraemic human immunodeficiency virus infection attributable to impairments in both PDC and NK cell function. J. Virol. 83, 11175–11187 (2009).
Ahlenstiel, G. et al. Natural killer cells are polarized towards cytotoxicity in chronic hepatitis C in an interferon-alfa–dependent manner. Gastroenterology 138, 325–335 (2010).
Bain, C. et al. Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection. Gastroenterology 120, 512–524 (2001).
Dolganiuc, A., Paek, E., Kodys, K., Thomas, J. & Szabo, G. Myeloid dendritic cells of patients with chronic HCV infection induce proliferation of regulatory T lymphocytes. Gastroenterology 135, 2119–2127 (2008).
Auffermann-Gretzinger, S., Keeffe, E. B. & Levy, S. Impaired dendritic cell maturation in patients with chronic, but not resolved, hepatitis C virus infection. Blood 97, 3171–3176 (2001).
Granelli-Piperno, A., Golebiowska, A., Trumpfheller, C., Siegal, F. P. & Steinman, R. M. HIV-1-infected monocyte-derived dendritic cells do not undergo maturation but can elicit IL-10 production and T cell regulation. Proc. Natl Acad. Sci. USA 101, 7669–7674 (2004).
Piccioli, D. et al. Comparable functions of plasmacytoid and monocyte-derived dendritic cells in chronic hepatitis C patients and healthy donors. J. Hepatol. 42, 61–67 (2005).
Tavakoli, S. et al. Peripheral blood dendritic cells are phenotypically and functionally intact in chronic hepatitis B virus (HBV) infection. Clin. Exp. Immunol. 151, 61–70 (2008).
Kamga, I. et al. Type I interferon production is profoundly and transiently impaired in primary HIV-1 infection. J. Infect. Dis. 192, 303–310 (2005).
Mengshol, J. A. et al. Impaired plasmacytoid dendritic cell maturation and differential chemotaxis in chronic hepatitis C virus: associations with antiviral treatment outcomes. Gut 58, 964–973 (2009).
Beignon, A. S. et al. Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor–viral RNA interactions. J. Clin. Invest. 115, 3265–3275 (2005).
Gondois-Rey, F. et al. Hepatitis C virus is a weak inducer of interferon alpha in plasmacytoid dendritic cells in comparison with influenza and human herpesvirus type-1. PLoS ONE 4, e4319 (2009). References 24, 25 and 90 provide the first evidence that HCV impairs the production of interferon-α in pDCs.
Krug, A. et al. Herpes simplex virus type 1 activates murine natural interferon-producing cells through toll-like receptor 9. Blood 103, 1433–1437 (2004).
Lund, J., Sato, A., Akira, S., Medzhitov, R. & Iwasaki, A. Toll-like receptor 9-mediated recognition of Herpes simplex virus-2 by plasmacytoid dendritic cells. J. Exp. Med. 198, 513–520 (2003).
Xu, Y. et al. HBsAg inhibits TLR9-mediated activation and IFN-α production in plasmacytoid dendritic cells. Mol. Immunol. 46, 2640–2646 (2009).
Martinelli, E. et al. HIV-1 gp120 inhibits TLR9-mediated activation and IFN-α secretion in plasmacytoid dendritic cells. Proc. Natl Acad. Sci. USA 104, 3396–3401 (2007).
Dzionek, A. et al. BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon α/β induction. J. Exp. Med. 194, 1823–1834 (2001).
Meyer-Wentrup, F. et al. Targeting DCIR on human plasmacytoid dendritic cells results in antigen presentation and inhibits IFN-α production. Blood 111, 4245–4253 (2008).
Mellor, A. L. & Munn, D. H. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nature Rev. Immunol. 4, 762–774 (2004).
Munn, D. H. et al. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J. Exp. Med. 189, 1363–1372 (1999).
Fallarino, F. et al. T cell apoptosis by tryptophan catabolism. Cell Death Differ. 9, 1069–1077 (2002).
Boasso, A. et al. HIV inhibits CD4+ T-cell proliferation by inducing indoleamine 2,3-dioxygenase in plasmacytoid dendritic cells. Blood 109, 3351–3359 (2007).
Manches, O. et al. HIV-activated human plasmacytoid DCs induce Tregs through an indoleamine 2,3-dioxygenase-dependent mechanism. J. Clin. Invest. 118, 3431–3439 (2008). This work provides evidence that immunodeficiency viruses induce suppressive T cells through the induction of IDO activity in pDCs.
Malleret, B. et al. Primary infection with simian immunodeficiency virus: plasmacytoid dendritic cell homing to lymph nodes, type I interferon, and immune suppression. Blood 112, 4598–4608 (2008).
Boasso, A. et al. Regulatory T-cell markers, indoleamine 2,3-dioxygenase, and virus levels in spleen and gut during progressive simian immunodeficiency virus infection. J. Virol. 81, 11593–11603 (2007).
Larrea, E. et al. Upregulation of indoleamine 2,3-dioxygenase in hepatitis C virus infection. J. Virol. 81, 3662–3666 (2007).
Chen, Y. B. et al. Immunosuppressive effect of IDO on T cells in patients with chronic hepatitis B. Hepatol. Res. 39, 463–468 (2009).
Coussens, L. M. & Werb, Z. Inflammation and cancer. Nature 420, 860–867 (2002).
Grossman, Z., Meier-Schellersheim, M., Paul, W. E. & Picker, L. J. Pathogenesis of HIV infection: what the virus spares is as important as what it destroys. Nature Med. 12, 289–295 (2006).
Mandl, J. N. et al. Divergent TLR7 and TLR9 signalling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections. Nature Med. 14, 1077–1087 (2008).
Meier, A. et al. Sex differences in the Toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1. Nature Med. 15, 955–959 (2009).
Crispe, I. N. The liver as a lymphoid organ. Annu. Rev. Immunol. 27, 147–163 (2009). An overview of the unique environment and composition of liver APCs. Antigen presentation in the liver often results in tolerance owing to the dominant presence of immunosuppressive cytokines and tolerogenic APCs.
Qian, S. et al. Murine liver allograft transplantation: tolerance and donor cell chimerism. Hepatology 19, 916–924 (1994).
Sumpter, T. L., Abe, M., Tokita, D. & Thomson, A. W. Dendritic cells, the liver, and transplantation. Hepatology 46, 2021–2031 (2007).
Royer, C. et al. A study of susceptibility of primary human Kupffer cells to hepatitis C virus. J. Hepatol. 38, 250–256 (2003).
Breiner, K. M., Schaller, H. & Knolle, P. A. Endothelial cell-mediated uptake of a hepatitis B virus: a new concept of liver targeting of hepatotropic microorganisms. Hepatology 34, 803–808 (2001).
Burgio, V. L. et al. Expression of co-stimulatory molecules by Kupffer cells in chronic hepatitis of hepatitis C virus aetiology. Hepatology 27, 1600–1606 (1998).
Crispe, I. N. Hepatic T cells and liver tolerance. Nature Rev. Immunol. 3, 51–62 (2003).
Radziewicz, H. et al. Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression. J. Virol. 81, 2545–2553 (2007).
Knolle, P. A. & Limmer, A. Neighborhood politics: the immunoregulatory function of organ-resident liver endothelial cells. Trends Immunol. 22, 432–437 (2001).
Warren, A. et al. T lymphocytes interact with hepatocytes through fenestrations in murine liver sinusoidal endothelial cells. Hepatology 44, 1182–1190 (2006).
Dienes, H. P., Hutteroth, T., Hess, G. & Meuer, S. C. Immunoelectron microscopic observations on the inflammatory infiltrates and HLA antigens in hepatitis B and non-A, non-B. Hepatology 7, 1317–1325 (1987).
Franco, A. et al. Expression of class I and class II major histocompatibility complex antigens on human hepatocytes. Hepatology 8, 449–454 (1988).
Bertolino, P., Trescol-Biemont, M. C. & Rabourdin-Combe, C. Hepatocytes induce functional activation of naive CD8+ T lymphocytes but fail to promote survival. Eur. J. Immunol. 28, 221–236 (1998).
Bowen, D. G. et al. The site of primary T cell activation is a determinant of the balance between intrahepatic tolerance and immunity. J. Clin. Invest. 114, 701–712 (2004).
Hilleman, M. R. Strategies and mechanisms for host and pathogen survival in acute and persistent viral infections. Proc. Natl Acad. Sci. USA 101 (Suppl. 2), 14560–14566 (2004).
Barth, H., Liang, T. J. & Baumert, T. F. Hepatitis C virus entry: molecular biology and clinical implications. Hepatology 44, 527–535 (2006).
Lindenbach, B. D. et al. Complete replication of hepatitis C virus in cell culture. Science 309, 623–626 (2005).
Wakita, T. et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nature Med. 11, 791–796 (2005).
Zhong, J. et al. Robust hepatitis C virus infection in vitro. Proc. Natl Acad. Sci. USA 102, 9294–9299 (2005). References 126–128 describe for the first time a cell culture system that allows the generation of recombinant infectious HCV. This system provides a powerful tool for studying the viral life cycle.
Pawlotsky, J. M. Pathophysiology of hepatitis C virus infection and related liver disease. Trends Microbiol. 12, 96–102 (2004).
Yi, M., Villanueva, R. A., Thomas, D. L., Wakita, T. & Lemon, S. M. Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells. Proc. Natl Acad. Sci. USA 103, 2310–2315 (2006).
Gottwein, J. M. et al. Development and characterization of hepatitis C virus genotype 1–7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs. Hepatology 49, 364–377 (2009).
Pietschmann, T. et al. Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc. Natl Acad. Sci. USA 103, 7408–7413 (2006).
Racanelli, V. & Rehermann, B. The liver as an immunological organ. Hepatology 43, S54–S62 (2006).
Acknowledgements
This work was supported by the CONECTUS-OSEO programme of the University of Strasbourg, France, the Deutsche Forschungsgemeinschaft, the intramural research programme of the National Institute of Diabetes and Digestive and Kidney Diseases (US National Institutes of Health), the European Union (through the programmes ERC HEPCENT and Interreg IV HEPATO-REGIO-NET), the French Agence Nationale de la Recherche, the French Agence Nationale de Recherche sur le SIDA et les Hépatites Virales, and the German Else Kröner-Fresenius Stiftung.
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Glossary
- Allogeneic
-
Describing an organ, tissue or cell from a donor of the same species as the recipient but with different histocompatibility antigens.
- Allograft
-
The transplantation of an allogeneic organ or tissue or allogeneic cells from a donor to a recipient. Also known as an allogeneic transplant.
- Tolerogenic
-
Non-responsive to a previously encountered antigen.
- Sinusoidal wall
-
A layer of liver sinusoidal endothelial cells that separates the sinusoidal blood (which is derived primarily from the portal vein) from hepatocytes.
Rights and permissions
About this article
Cite this article
Lambotin, M., Raghuraman, S., Stoll-Keller, F. et al. A look behind closed doors: interaction of persistent viruses with dendritic cells. Nat Rev Microbiol 8, 350–360 (2010). https://doi.org/10.1038/nrmicro2332
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrmicro2332
This article is cited by
-
Differentiation, maturation, and collection of THP-1-derived dendritic cells based on a PEG hydrogel culture platform
Biotechnology Letters (2024)
-
Dendritic Cell–Targeted Therapies to Treat Neurological Disorders
Molecular Neurobiology (2022)
-
Actin-depolymerizing factor from Eimeria tenella promotes immunogenic function of chicken dendritic cells
Parasitology Research (2021)
-
High dimensional profiling identifies specific immune types along the recovery trajectories of critically ill COVID19 patients
Cellular and Molecular Life Sciences (2021)
-
Antiretroviral therapy partially improves the abnormalities of dendritic cells and lymphoid and myeloid regulatory populations in recently infected HIV patients
Scientific Reports (2019)